These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 16236682

  • 1. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S, Larsson AM.
    Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
    [Abstract] [Full Text] [Related]

  • 2. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 8. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V, Knopf KB, Norris LB, Chen B, Yang YT, Qureshi ZP, Hrushesky W, Lebby AA, Schooley B, Hikmet N, Dickson M, Thamer M, Cotter D, Yarnold PR, Bennett CL.
    J Oncol Pract; 2017 Jun; 13(6):e562-e573. PubMed ID: 28504901
    [Abstract] [Full Text] [Related]

  • 9. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.
    Am J Health Syst Pharm; 2005 Jan 01; 62(1):54-62. PubMed ID: 15658073
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar 01; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 11. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Mar 01; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J, Jorgenson J, Johnson PE, Brophy DF, Comstock T, Feng A, Audhya P.
    Am J Health Syst Pharm; 2008 Sep 15; 65(18):1711-9. PubMed ID: 18768997
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 15; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.
    Clin Ther; 2006 Jun 15; 28(6):801-31. PubMed ID: 16860166
    [Abstract] [Full Text] [Related]

  • 16. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G, Hurley D, Whyte JL, Willey V, Wilson M, Kallich J.
    Curr Med Res Opin; 2009 Jul 15; 25(7):1775-84. PubMed ID: 19505205
    [Abstract] [Full Text] [Related]

  • 17. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH.
    Drugs; 2007 Jul 15; 67(2):175-94. PubMed ID: 17284083
    [Abstract] [Full Text] [Related]

  • 18. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC.
    Ann Pharmacother; 2006 May 15; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract] [Full Text] [Related]

  • 19. Darbepoetin for the anaemia of chronic kidney disease.
    Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Mar 31; 2014(3):CD009297. PubMed ID: 24683046
    [Abstract] [Full Text] [Related]

  • 20. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008 Mar 31; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.